Physician profile
Kambiz T Karimi
NPI 1720061823
$17,293.89
in general payments reported to CMS, 2019-2025
21 companies · $46.00 in 2025
The $46.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,837 · 2021: $3,298 · 2022: $720 · 2023: $837 · 2024: $513 · 2025: $46.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $11,754.85 | 2019-2024 | Sublocade |
| Allergan, INC. | $1,779.97 | 2019-2020 | |
| Abbvie INC. | $844.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $734.19 | 2019-2024 | Trintellix |
| Almatica Pharma LLC | $581.19 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $290.97 | 2020-2022 | |
| Alkermes, INC. | $246.56 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.11 | 2022 | |
| Merck Sharp & Dohme LLC | $175.73 | 2021-2023 | Belsomra |
| Gilead Sciences, INC. | $139.01 | 2019-2021 | |
| Axsome Therapeutics, INC. | $101.90 | 2023-2024 | Auvelity |
| Orexo US, INC. | $86.26 | 2019-2021 | |
| Pfizer INC. | $69.47 | 2019-2021 | |
| Adlon Therapeutics L.P. | $54.47 | 2020-2021 | |
| Mdd US Operations, LLC | $54.12 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $40.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.49 | 2019-2023 | Xifaxan |
| Uswm, LLC | $36.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.69 | 2021 | |
| Bausch Health US, LLC | $17.47 | 2021 | |
| Masimo Corporation | $16.25 | 2023 | Emma and Isa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kambiz Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.